| API | active pharmaceutical ingredient |
| API–OSILs | active pharmaceutical ingredient organic salts and ionic liquids |
| C16Py | cetylpyridinium |
| C2OHDMIM | 1-(2-hydroxyethyl)-2,3-dimethylimidazolium |
| C2OHMIM | 1-(2-hydroxyethyl)-3-methylimidazolium |
| C3OMIM | 1-(2-methoxyethyl)-3-methylimidazolium |
| Ch | choline |
| Cip | ciprofloxacin |
| CMC | critical micelle concentration |
| EMIM | 1-ethyl-3-methylimidazolium |
| FQ | fluoroquinolone |
| FQ-OSILs | fluoroquinolone-based organic salts and ionic liquids |
| FTIR | Fourier-transform infrared spectroscopy |
| IC50 | half maximal inhibitory concentration |
| IL | ionic liquid |
| NMR | nuclear magnetic resonance |
| Nor | norfloxacin |
| OSIL | organic salt and ionic liquid |
| RDIC50 | relative decrease in inhibitory concentration for 50% bacterial growth |
| RTILsSEM | room temperature ionic liquidsstandard error mean |
| Tg | glass transition temperature |
| Tm | melting temperature |